Postoperative Ileus — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for postoperative ileus. 1 active patents protecting 1 drugs from 1+ originators. First major cliff: 2030. Daily refresh.

1
Approved drugs
1
Active US patents
68/100
Avg vulnerability
—
Annual revenue covered

Originators in Postoperative Ileus

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Cubist Pharms 1 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating postoperative ileus. Each bar = one year. Y-axis scaled to peak year (1 patents).

1
30

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Entereg
ALVIMOPAN
 Cubist Pharms 1 68 — 2030-02-12

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8946262 Entereg method of use 68 2030-02-12

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8946262 Entereg method of use 68 2030-02-12

Related